Beta Finch - Income & Dividends - EN

**BETA FINCH PODCAST SCRIPT****ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown where we dive into the latest quarterly results and what they mean for investors. I'm Alex.**JORDAN**: And I'm Jordan. Today we're breaking down Colgate-Palmolive's Q1 2026 earnings call, and there's quite a bit to unpack here.**ALEX**: Before we jump in, I need to share our standard disclaimer: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.**JORDAN**: Absolutely. Now, Alex, Colgate had an interesting quarter - some really strong performance in certain areas, but they're also dealing with significant headwinds. Where do you want to start?**ALEX**: Let's kick off with the headline numbers. Colgate delivered what CEO Noel Wallace called "strong top and bottom line growth" with organic sales growth actually accelerating from Q4. They saw growth in both volume and pricing across all four categories and four of five divisions, which is pretty impressive breadth.**JORDAN**: That's right, and what really caught my attention was the geographic mix. Emerging markets were the star of the show, particularly Asia Pacific. Wallace mentioned that these are regions where Colgate's global brands have higher market shares and greater scale advantages, so they're doubling down on investments there.**ALEX**: Speaking of investments, they're maintaining their focus on brand equity and advertising spending, which is notable given the cost pressures they're facing. But Jordan, let's talk about the elephant in the room - that $300 million increase in expected raw material and logistics costs.**JORDAN**: Yeah, this is where things get interesting from a margins perspective. They had to revise their gross margin outlook downward because of these cost pressures. CFO Stanley Sutula broke it down - about two-thirds of that $300 million hit is from raw materials, one-third from logistics. The big culprits? Oil byproducts like resins and petrochemicals, with spending in those areas expected to be up more than 20% year-over-year.**ALEX**: And they're assuming crude oil at around $110 for their planning purposes. But here's what I found encouraging - despite these headwinds, they reaffirmed their full-year guidance for both top and bottom line growth. How are they managing to do that?**JORDAN**: It comes down to what Wallace calls their "flexible P&L model." They're offsetting these cost pressures through several levers: revenue growth management, or RGM, productivity initiatives, and they just announced an acceleration of their Strategic Growth and Productivity Program - or SGPP.**ALEX**: Let's dig into that SGPP announcement because it's pretty significant. They're now targeting $200 million to $300 million in annualized savings, with most of those savings hitting in 2027 and 2028. Wallace emphasized this isn't an extension of the program - it's still completing by end of 2028 - but they've identified additional opportunities.**JORDAN**: Right, and Sutula explained that the strong execution from their teams allowed them to reach the high end of their initial targets, plus they found new ways to simplify operations and enhance efficiency. I like that they're being proactive about organizational structure and reducing complexity.**ALEX**: Now, the regional performance was really telling. Asia Pacific was a standout, with improvements in both China through their Hawley & Hazel business and strong performance in India. Wallace mentioned they're not "completely out of the woods" in China yet, but the interventions they've made - accelerated innovation, better omnichannel execution - are starting to pay off.**JORDAN**: Latin America also had another strong volume quarter with mid-single-digit growth. Wallace was particularly enthusiastThis episode includes AI-generated content.

**BETA FINCH PODCAST SCRIPT**---**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we turn complex financial reports into clear, actionable insights. I'm Alex.**JORDAN:** And I'm Jordan. Today we're diving into Altria Group's Q1 2026 earnings call - and wow, there's a lot to unpack here, including a CEO transition and some fascinating market dynamics in both cigarettes and nicotine pouches.**ALEX:** Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.**JORDAN:** Absolutely. Now, let's talk numbers first. Altria delivered a solid start to 2026 with adjusted diluted EPS growing 7.3% in Q1. They're maintaining their full-year guidance of $5.56 to $5.72 per share, which represents 2.5% to 5.5% growth.**ALEX:** That's a strong performance, but what really caught my attention was the underlying story about consumer behavior. Jordan, can you break down what's happening in the cigarette market?**JORDAN:** Sure thing. So there are two major trends colliding here. First, we're seeing moderation in the e-vapor category - particularly those illicit flavored disposable products that have been stealing cigarette smokers for years. Federal and state enforcement is finally having an impact, and it looks like the category may have hit a saturation point.**ALEX:** Which is helping cigarette volumes, right? They declined only 4% when adjusted for trade inventory movements, compared to much steeper declines we've seen in recent years.**JORDAN:** Exactly. But here's the fascinating part - all of this volume improvement is happening in the discount segment, not premium. Consumers are under serious economic pressure. Gas prices spiked, inflation is still biting, and people are trading down to cheaper brands.**ALEX:** And Altria is capturing that trade-down with their Basic brand. The numbers here are pretty impressive - Basic grew 2.4 share points year-over-year in the discount segment. Meanwhile, Marlboro actually lost 1.4 share points overall but gained in the premium segment specifically.**JORDAN:** That's the beauty of their portfolio strategy. They're essentially playing both ends of the market. When premium smokers stay loyal, Marlboro captures them. When economic pressure forces people to trade down, Basic is there waiting.**ALEX:** Now let's talk about the growth story - oral nicotine pouches. This category is absolutely exploding. Jordan, what's happening with their on! brand?**JORDAN:** The oral nicotine pouch segment now represents 58% of the total oral tobacco category - that's remarkable growth. Altria's on! portfolio shipped nearly 18% more volume, hitting over 46 million cans in Q1. They launched on! PLUS nationwide in March, and it's already in about 100,000 stores.**ALEX:** What makes on! PLUS special?**JORDAN:** Two things: it's the first and only product authorized under the FDA's pilot program for nicotine pouches, which should give them a regulatory advantage. And they're marketing it as "the softest pouch on the planet" using their proprietary NICOSILK technology. They're really trying to differentiate on the user experience.**ALEX:** Speaking of the FDA, there was interesting commentary about the regulatory environment. CEO William Gifford - and by the way, this was his final earnings call - was pushing hard for the FDA to streamline authorizations for e-vapor products.**JORDAN:** Right, and his logic makes sense. The e-vapor category is still about 70% illicit products. Gifford argued that faster authorizations combined with sustained enforcement could create a compliant marketplace where authorized manufacturers can serve adult consumers with quality products.**ALEX:** Let's talk about that CEO transition. Gifford is stepping dThis episode includes AI-generated content.

# Beta Finch Podcast Script: Coca-Cola Q1 2026 Earnings**ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown where we dive deep into the numbers that matter. I'm Alex, and joining me as always is my co-host Jordan. Today we're breaking down Coca-Cola's Q1 2026 earnings - and folks, this was a strong start to the year for the beverage giant.Before we jump in, I need to share an important disclaimer: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.**JORDAN**: Thanks Alex. And what a quarter this was for Coca-Cola! Let me hit you with the headline numbers first. The company delivered 10% organic revenue growth with 3% volume growth across all segments. That's particularly impressive when you consider the challenging macro environment we're seeing globally.**ALEX**: Absolutely. And Jordan, what really caught my attention was the earnings per share performance - 18% growth to 86 cents per share on a comparable basis. That's solid double-digit growth that beat expectations. CEO Henrique Braun seemed pretty confident about their "balanced growth algorithm" approach.**JORDAN**: Right, and that's a key theme throughout this call - this idea of balancing volume growth with price/mix improvements. They managed 3% volume growth and 2% price/mix growth in Q1, which Braun described as exactly the kind of balanced approach they're targeting. He mentioned they might see this flip to 2% volume and 3% price/mix in other quarters, but the goal is maintaining that balance.**ALEX**: Now, there were some interesting regional dynamics here. North America showed solid performance with volume and value share gains, but they had some headwinds from Easter timing and category mix issues, particularly with packaged water and production constraints on Topo Chico and Fairlife.**JORDAN**: And speaking of Fairlife - which investors have been watching closely - Braun confirmed that the Webster facility capacity is coming online in Q2 as planned, which should help address those production constraints. That's a key capacity expansion for their growing dairy business.**ALEX**: Let's talk about some of the geographic highlights because this really shows Coke's global reach. In Latin America, they gained value share despite challenges in Mexico from the sugar tax that was implemented at the beginning of the year. But Brazil and Central America more than offset those declines.**JORDAN**: And in EMEA - that's Europe, Middle East, and Africa - they gained value share and grew volume across all operating units, despite some obvious challenges from the Middle East conflict. Braun noted that while they grew volume for the quarter overall, volumes did decline in March after the onset of that conflict.**ALEX**: The Asia Pacific region is particularly interesting from a strategic standpoint. They grew volume across all operating units despite cycling a tough comparison from the prior year. But Jordan, the margin story there was concerning - operating margins compressed almost 10 percentage points.**JORDAN**: That's right Alex, and CFO John Murphy addressed this directly. About two-thirds of that margin compression was due to a one-time inventory issue, particularly phasing of juice inventory costs in China. They also had commodity pressures in tea and coffee businesses. Murphy emphasized this was largely a Q1 anomaly and they expect improvement as the year progresses.**ALEX**: One thing that really stood out in the Q&A was the discussion around innovation and consumer centricity. Braun talked about their "4 I's" approach - insight, innovation, intimacy, and integrated execution. They highlighted the success of Coca-Cola Zero-Zero in Europe, which targets consumers who want to reduce caffeine intake in the evening.**JORDAN**: That'sThis episode includes AI-generated content.

**BETA FINCH PODCAST SCRIPT**---ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, and I'm here with my co-host Jordan to dive into 3M's first quarter 2026 results. Jordan, this was quite an interesting call from the industrial giant.JORDAN: Absolutely, Alex. And before we jump in, I want to remind our listeners that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.ALEX: Thanks for that, Jordan. Now, let's talk 3M. The headline numbers were pretty solid - earnings per share of $2.14, up mid-teens from last year, and operating margins improved 30 basis points to 23.8%. But the revenue story was a bit more nuanced, wasn't it?JORDAN: That's right. Organic growth came in at just 1.2% for the quarter, which CEO Bill Brown called a "light start to the year." But here's what caught my attention - orders were up over 10%, and backlog grew double digits both sequentially and year-over-year. That's typically a good leading indicator.ALEX: And Brown seemed pretty confident about that acceleration, didn't he? He kept emphasizing that they expect growth to pick up in Q2 and the back half of the year. What do you think is driving that optimism?JORDAN: Well, there are a few factors. First, they're seeing strong momentum in what they call their "commercial excellence" initiatives - basically better sales effectiveness and reduced customer churn. They've already captured $80 million of new business against a three-year target of $100 million. Plus, they're launching new products at an accelerated pace - 84 new products in Q1, up 35% from last year.ALEX: I was fascinated by their AI initiatives. They mentioned using AI tools to analyze sales data and create customized coaching plans for sales managers. And there's this "Ask 3M Company" AI assistant that helps customers find solutions. It feels like they're really embracing technology to drive growth.JORDAN: Absolutely. And speaking of technology, one of the most interesting parts of the call was their discussion of the data center business. They highlighted expanded beam optics - or EBO - which is apparently a high-performance optical connector for data centers. With hyperscaler validation and what they called a "billion-dollar-plus addressable market," they're investing to more than double capacity.ALEX: That ties into the broader AI and data center boom we're seeing across the market. But let's talk about some of the challenges. They mentioned softness in consumer electronics and automotive, which affected about 40% of their portfolio.JORDAN: Right, and this is where the story gets interesting from a portfolio management perspective. Brown talked about how roughly 60% of their businesses showed strength, while 40% faced macro headwinds. In electronics, they saw strong performance in semiconductors and data centers, but consumer electronics was soft due to what they called "industry-wide memory chip issues."ALEX: And then there was this interesting discussion about pre-buying. CFO Anurag Maheshwari and Brown acknowledged that some of the strong order growth might have been customers buying ahead of price increases. How significant do you think that was?JORDAN: It's hard to quantify, but they seemed to suggest it was a factor. They're implementing price increases due to rising oil costs - about $125 million of cost impact that they're offsetting with roughly 50 basis points of additional pricing. Brown mentioned they learned from their experience with tariffs and are moving much faster on pricing this time.ALEX: Let's talk about their operational transformation. They're really reshaping this company, aren't they? They mentioned reducing their manufacturing footprint to below 100 facilities.JORDAN: That's a major shift. They closed or announThis episode includes AI-generated content.

**BETA FINCH PODCAST SCRIPT**---**ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown where we dive into the numbers that matter. I'm Alex, and I'm here with my co-host Jordan to break down PepsiCo's Q1 2026 earnings call. Jordan, this was quite an interesting quarter with some geopolitical backdrop we don't usually see.**JORDAN**: Absolutely, Alex. And before we jump into the numbers, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.**ALEX**: Thanks, Jordan. Now, let's talk PepsiCo. The big headline here is that they're showing sequential improvement across their business units, particularly in North America Foods, which has been a challenge area. They maintained their organic revenue guidance of 2% to 4% for the year, with expectations to hit the higher end in the back half.**JORDAN**: Right, and what's fascinating is how they're navigating this Iran conflict situation. CFO Steve Schmitt was pretty transparent about it - they have 6 to 12-month hedging programs in place, and surprisingly, they're not seeing major supply chain disruptions. In fact, CEO Ramon Laguarta mentioned they might actually have better supply chain resilience than some competitors, especially in the food business.**ALEX**: That's a great point about competitive advantage during tough times. Let's break down the segment performance. The North America Foods business, which has been under pressure, showed 2% volume growth in Q1. Jordan, this seems like a real turnaround story.**JORDAN**: It really is, Alex. What's impressive is the scale of this turnaround - they added 300 million new consumption occasions in Q1 compared to the same period last year. That's massive. Ramon talked about this being a "holistic commercial strategy" involving better value propositions, more shelf space, brand restaging for Lay's and Tostitos, and accelerated innovation in what they call "permissible and functional" products.**ALEX**: And they're seeing results in market share too, right? They mentioned gaining positive share in both volume and value recently, which had been a key performance indicator they set for themselves.**JORDAN**: Exactly. The away-from-home business is growing at 3x the company average, and their permissible portfolio brands like SunChips and Smartfood are seeing double-digit growth in some cases. But here's what I found most interesting - their costs for North America Foods actually went *down* in Q1 while they're investing more. That speaks to their productivity initiatives really paying off.**ALEX**: That productivity story is huge. Let's talk about the beverage side - PBNA grew 9% total, which is pretty impressive.**JORDAN**: Yeah, but it's a mixed bag when you dig deeper. The headline 9% growth includes about 7 points from new platforms and acquisitions like Poppi and expanded energy drink distribution. The organic growth was around 2%. They're still dealing with a case pack water transition that pressured volumes, but Ramon expects that to turn positive in coming quarters.**ALEX**: One thing that stood out from the Q&A was the discussion around SNAP benefit restrictions and GLP-1 drugs. These are newer headwinds the industry is watching closely.**JORDAN**: True, eight states began SNAP restrictions in Q1, mainly affecting beverages and candy. But Steve Schmitt said it's too early to draw conclusions. What's more interesting is how they're positioning for these secular changes - they're doubling down on innovation in functional and permissible products, which could actually benefit from health-conscious trends.**ALEX**: The international business seems to be firing on all cylinders. Ramon mentioned they haven't seen demand impact from the Iran conflict and are actually accelerating inThis episode includes AI-generated content.

**BETA FINCH PODCAST SCRIPT**---**ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex, and I'm here with my co-host Jordan to dive into Abbott Laboratories' Q1 2026 earnings call. Jordan, this was a pretty significant quarter for Abbott - they just closed their acquisition of Exact Sciences back in March.**JORDAN**: Absolutely, Alex. And before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.**ALEX**: Thanks for that reminder. So let's talk numbers first. Abbott reported adjusted earnings per share of $1.15 for Q1, which was right in line with their guidance despite some headwinds. Revenue-wise, they're now reporting what they call "comparable growth" of 3.7%, which includes Exact Sciences in both current and prior year numbers.**JORDAN**: That comparable growth metric is really interesting, Alex. CEO Robert Ford explained they're doing this to give investors a cleaner apples-to-apples view of the combined business. It's similar to what they did during COVID when they separated out COVID sales, or when they acquired St. Jude. The goal is transparency.**ALEX**: Right, and looking forward, they've updated their full-year guidance to 6.5% to 7.5% comparable sales growth. But here's what caught my attention - their adjusted EPS guidance midpoint dropped from $5.68 to $5.48. That $0.20 dilution is directly from the Exact Sciences acquisition, which was expected.**JORDAN**: Let's break down the business segments because there were some really interesting dynamics. Medical Devices was the star performer with 8.5% growth. The Electrophysiology business grew 13%, and get this - they had earlier-than-planned approvals for two new pulsed field ablation catheters.**ALEX**: Those PFA catheters are a big deal, Jordan. The Volt PFA catheter helped drive 14% growth in the U.S., while the TactiFlex Duo catheter contributed to mid-teens growth in Europe. Ford seemed pretty bullish about acceleration in the EP business as these launches broaden.**JORDAN**: And speaking of acceleration, the continuous glucose monitoring business had some interesting dynamics. CGM sales were $2 billion but only grew 7.5% due to an international tender delay and some tough comparisons from last year's shelf restocking. But management expects a return to double-digit growth in Q2.**ALEX**: That's a key point. During the Q&A, Ford was asked about concerns that the CGM market might be saturated. His response was fascinating - he said they estimate 70 to 80 million people globally should be on CGM, but the current market is only 10 to 12 million people. That's massive underpenetration.**JORDAN**: He also mentioned some upcoming catalysts, including expected CMS coverage for type 2 non-insulin patients, which could add close to 10 million people who currently don't have coverage. Ford was very clear he hadn't baked that into guidance, so it could be upside if it materializes.**ALEX**: Now let's talk about the Exact Sciences integration. This was really the elephant in the room. Ford named Jake Orville to lead that business, reporting directly to him. The Cologuard business grew 13% on a comparable basis, with mid-teens growth of the core Cologuard product.**JORDAN**: What struck me was Ford's long-term vision here. He doesn't see this as just a one-product deal, but as a beachhead into the entire cancer diagnostics space - screening, therapy selection, and MRD testing. He pointed out that about 50 million Americans aren't up to date with colorectal cancer screening.**ALEX**: And internationally, Ford said it's very underpenetrated. Abbott brings established regulatory and distribution relationships that could really accelerate international expansion. He even mentioned traveling toThis episode includes AI-generated content.

**BETA FINCH PODCAST SCRIPT**---**ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex, and I'm here with my co-host Jordan to dive into Philip Morris International's Q4 2025 earnings call. Now before we get started, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.**JORDAN**: Thanks Alex! And what a call this was from Philip Morris. They absolutely crushed it in 2025, delivering what CEO Jacek Olczak called "another outstanding year." We're talking about their fifth consecutive year of positive volumes, driven primarily by their smoke-free products business.**ALEX**: Right, and the numbers really tell the story here. Philip Morris hit over $40 billion in total net revenues for 2025, with smoke-free products now representing 41.5% of that - nearly $17 billion! That's a massive shift from where they were just a few years ago.**JORDAN**: The growth trajectory is impressive. Smoke-free product volumes grew 12.8%, with IQOS leading the charge at 11% growth. But here's what caught my attention - their ZYN nicotine pouches in the US grew shipments by 37%, despite supply constraints. That's reaching 11.9 billion pouches, making up about 7% of their total smoke-free volume.**ALEX**: And let's talk profitability because that's where this story gets really interesting. Their smoke-free gross margin hit 69.5%, which is now four percentage points higher than their combustible business. CFO Emmanuel Babeau made it clear that this improving profitability mix is a key driver of their overall margin expansion.**JORDAN**: Speaking of margins, they delivered 140 basis points of organic margin expansion to reach 40.4% adjusted operating margin. That's while they're still investing heavily in marketing and brand building for their smoke-free portfolio. It shows real operating leverage in the business model.**ALEX**: Now, the guidance for 2026 is where things get particularly interesting. They're forecasting organic net revenue growth of 5-7%, which might seem modest compared to recent years, but there are some specific headwinds they're navigating.**JORDAN**: Exactly. The big story is Japan, where they're facing significant excise tax increases on heated tobacco products - we're talking 50-100 yen per pack, which could be 10-20% of current retail prices. This creates an asymmetry where heated tobacco gets hit first, before cigarettes face similar increases in 2027.**ALEX**: And in the US, there's the ZYN inventory normalization. They estimate there are about 25 million cans of surplus inventory in the downstream supply chain that needs to work through, likely in Q1. But the underlying demand story remains strong - ZYN maintained about 61.5% volume share in the US nicotine pouch category.**JORDAN**: What I found fascinating in the Q&A was the discussion around ZYN Ultra, their higher-strength nicotine pouch that's pending FDA approval. Olczak was pretty direct - they have readiness to launch "essentially as we speak," and they're expecting some movement this summer, though he admitted he doesn't have a great track record forecasting the FDA!**ALEX**: [Laughs] At least he's honest about that! But you can tell they're frustrated with the regulatory environment. When asked about New York's proposed excise tax on nicotine pouches, Olczak called it "counterproductive to the health benefits" and "the wrong idea."**JORDAN**: The international expansion story is really compelling too. They're now in 106 markets with smoke-free products, and some of these new launches are showing impressive traction. Taiwan caught my eye - they hit 4% market share in just a few weeks after launch. That's remarkable penetration for a new market entry.**ALEX**: And they're not just focused on IQOS anyThis episode includes AI-generated content.

**BETA FINCH PODCAST SCRIPT**---**ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, and I'm here with my co-host Jordan to dive into Procter & Gamble's Q2 2026 earnings call. Before we get started, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.**JORDAN**: Thanks Alex. And what a quarter to unpack! P&G just reported what management called their "softest quarter of the fiscal year," but there's actually a lot more optimism here than that headline might suggest.**ALEX**: Absolutely. Let's start with the numbers, Jordan. Organic sales were flat year-over-year, which sounds underwhelming until you understand the context. They had some major base period disruptions - remember those port strikes and hurricanes last October that caused all that inventory loading?**JORDAN**: Right, and CFO Andre Schulten was very clear about this. The biggest impacts hit baby care, feminine care, and family care - all concentrated in the U.S. market. But here's the interesting part: the rest of P&G's business outside the U.S. actually grew nearly 3%. That's a pretty solid foundation.**ALEX**: That's a great point. When you look at the regional breakdown, you see some real bright spots. Latin America grew 8%, Greater China was up 3% - which is impressive given the challenging consumer environment there. Europe's enterprise markets grew 6%. It really was a U.S.-centric slowdown.**JORDAN**: And speaking of China, I loved CEO Shailesh Jejurikar's example about their Pampers Prestige innovation. They tapped into this deep cultural insight about Chinese parents wanting the best for their babies, and literally incorporated silk - this symbol of luxury for over 2,000 years - into their diapers. It's driving double-digit growth and they've gained nearly three points of market share.**ALEX**: That's exactly the kind of consumer-centric innovation P&G is doubling down on. Jejurikar talked extensively about what he called "the next important phase of constructive disruption." They're not just tweaking around the edges - they're fundamentally reimagining how a CPG company operates in today's fragmented media landscape.**JORDAN**: The technology transformation really stood out to me. They've built this massive data lake with petabytes of consumer information, AI-powered tools for product development, and supply chain systems that can react autonomously to demand signals. But Jejurikar was realistic about the timeline - he said it'll take 12 to 18 months to get this "future evenly distributed" across the company.**ALEX**: Let's talk margins for a second. Core EPS came in at $1.88, flat with last year. But they delivered 270 basis points of productivity improvements, which they reinvested back into innovation and marketing. That's classic P&G - they're not letting a tough quarter derail their long-term investment strategy.**JORDAN**: And they're maintaining all their full-year guidance, which shows real confidence. Organic sales growth of flat to plus 4%, core EPS growth of flat to plus 4%. They're basically saying "trust us, the back half is going to be much stronger."**ALEX**: The Q&A session revealed some interesting dynamics too. When analysts pressed about U.S. market share losses, Schulten was pretty direct - they have work to do to recover share, but they're already seeing progress in categories like family care and laundry where they've made those innovation interventions.**JORDAN**: I thought the discussion about e-commerce was fascinating. One analyst pointed out that Amazon is driving 60-80% of growth in P&G's categories. Jejurikar's response was telling - they're being very deliberate about winning in fast-growing channels, and in some markets like India, their e-commerce shareThis episode includes AI-generated content.

**Beta Finch Podcast Script: Altria (MO) Q4 2025 Earnings**ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, and I'm joined by my co-host Jordan. Today we're diving into tobacco giant Altria's fourth quarter 2025 results. Before we get started, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.JORDAN: Thanks Alex. And wow, what a quarter for Altria. The company delivered some solid financials but also took a massive $1.3 billion impairment charge on their e-vapor business. That's not exactly chump change.ALEX: Absolutely not. Let's start with the big picture numbers. Altria grew adjusted earnings per share by 4.4% for the full year and returned a whopping $8 billion to shareholders through dividends and share buybacks. That's serious cash returning to investors.JORDAN: Right, and they're guiding for 2026 EPS between $5.56 and $5.72, which represents 2.5% to 5.5% growth. But here's the interesting part - CEO Billy Gifford said that growth will be "weighted to the second half of the year." That suggests a slower start to 2026.ALEX: That timing issue ties into one of their big strategic moves. Altria is investing heavily in what they call "import-export capabilities" - basically a duty drawback program where they can manufacture cigarettes for international markets and then reimport them to get tax benefits. It's a complex play, but CFO Sal Mancuso said it has a payback period of less than a year.JORDAN: That's actually pretty clever from a financial engineering standpoint. But let's talk about the elephant in the room - that $1.3 billion e-vapor impairment. They acquired NJOY to get into the vaping space, but the market is absolutely dominated by illegal flavored disposables from China.ALEX: Exactly. Gifford said illegal products represent about 70% of the e-vapor category. Think about that - seven out of ten vaping products sold in the US are essentially operating outside FDA regulations. That makes it nearly impossible for legitimate companies like Altria to compete profitably.JORDAN: But there might be a silver lining here. The company is seeing early signs that federal enforcement is starting to bite. Disposable e-vapor volume growth slowed from over 50% in 2024 to about 30% in 2025. Plus, Congress allocated at least $200 million in tobacco user fees specifically for enforcement activities.ALEX: That enforcement angle is crucial for understanding Altria's strategy. They're basically saying "we'll wait on the sidelines until the government cleans up the illegal competition." Meanwhile, they're focusing on their nicotine pouch business, which is actually performing pretty well.JORDAN: Speaking of nicotine pouches, their ON! brand is interesting. They got FDA authorization for ON! PLUS in December - that's their premium product with what they call "innovative pouch material and smooth flavor." They're positioning it as a premium option that can command higher prices than their classic ON! pouches.ALEX: The numbers back that up. Helix, which makes the ON! products, shipped over 177 million cans for the full year, up about 11%. And while competitors were cutting prices - down 12% year-over-year according to Altria - they actually raised ON! prices by 3%.JORDAN: But let's be real about the core business. Cigarette volumes declined 10% for the full year. That's a serious headwind. Even more concerning, Marlboro's retail share dropped below 40% for the first time ever.ALEX: That Marlboro number caught my attention too. But Gifford pushed back on concerns during the Q&A, saying they're focused on "maximizing profitability over the long term" rather than chasing market share. They're also aggressively promoting their Basic discount brand in about 30,000 stores tThis episode includes AI-generated content.

**BETA FINCH PODCAST SCRIPT**---**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we turn quarterly calls into coffee-shop conversations. I'm Alex, and I'm here with my co-host Jordan to break down 3M's Q4 2025 earnings call that just wrapped up. Jordan, this was one of those calls where the CEO really wanted to drive home that the turnaround is working.**JORDAN:** Absolutely, Alex. And before we dive in, let me quickly mention - this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.**ALEX:** Thanks for that reminder. Now, let's get into the numbers because 3M delivered some solid results here. Organic growth of 2.2% in Q4, operating margin of 21.1%, and earnings per share came in at $1.83. But the real story is the full-year performance - they grew organic sales 2.1% for the year, which is a nice acceleration from that 1.2% they posted in 2024.**JORDAN:** What really caught my attention was the margin expansion story. They delivered 23.4% adjusted operating margin for the full year - that's up 200 basis points year-over-year and at the high end of their guidance. CEO Bill Brown has been hammering this "commercial excellence" message for the past 21 months, and it seems like it's actually working.**ALEX:** Yeah, and let's talk about innovation because this is where things get interesting. They launched 284 new products in 2025 - that's up 68% from the prior year. Brown was pretty excited about this, saying sales from products launched in the last five years were up 23% for the full year.**JORDAN:** That's a key metric to watch, Alex. They call it their "new product vitality index" or NPVI, and it hit 13% - about two points above where they started the year. But here's what I found fascinating - Brown said about 80% of their R&D spending is now focused on what they call "priority verticals" - the higher-growth, higher-margin areas.**ALEX:** Right, and speaking of those priority verticals, they represent about 60% of the business now. Brown hinted that there's going to be some portfolio reshuffling ahead. He mentioned about 10% of their business is in more commodity-like areas that they're probably going to think about exiting over time.**JORDAN:** The operational metrics were impressive too. Their OTIF - that's on-time, in-full delivery - hit 90%, up 300 basis points from the prior year. Brown called it "the best we've achieved in decades" and they sustained that rate for seven months straight. That's the kind of operational excellence that actually moves the needle with customers.**ALEX:** Now let's talk guidance because this is where it gets really interesting for investors. For 2026, they're calling for organic sales growth of approximately 3% - so accelerating from that 2.1% they just posted. They expect adjusted operating margin expansion of 70 to 80 basis points, and EPS of $8.50 to $8.70.**JORDAN:** What I like about this guidance is the confidence in their "outgrowth" strategy. Brown said they expect the macro environment to be around 1.7% growth, but they're guiding to 3% organic growth. That delta - over $300 million - is what he calls outperforming the macro, and about half of that is coming from new product introductions.**ALEX:** The Q&A had some interesting moments too. There were several questions about tariffs, which makes sense given the current political environment. Brown said they're already dealing with about $140 million in gross tariff impact, and there could be additional headwinds if new Europe tariffs get implemented.**JORDAN:** Yeah, Brown was pretty measured on that topic. He said if the proposed Europe tariffs play out as discussed - 10% initially, then up to 25% - it could be a $30 to $40 million impact in 2026. But he emphasized that's not in their guiThis episode includes AI-generated content.

**BETA FINCH PODCAST SCRIPT****[INTRO MUSIC]**ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex, and I'm here with my co-host Jordan to dive into McDonald's Q4 2025 results. Jordan, this was quite the quarter for the Golden Arches.JORDAN: Absolutely, Alex! And before we dig in, I need to mention - this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.ALEX: Thanks for that reminder, Jordan. Now, let's talk numbers. McDonald's delivered some impressive results - system-wide sales hit nearly $140 billion, up 5.5% in constant currency for the full year. But what really caught my eye was that Q4 comp sales growth of 5.7% globally. That's pretty strong in what they're calling a "challenging industry backdrop."JORDAN: Right, and breaking that down by segment - the U.S. was particularly strong at 6.8% comp growth, well above expectations. What's interesting is they had positive guest counts, which is always a key indicator of sustainable growth. CEO Chris Kempczinski mentioned they achieved their highest quarterly comparable guest count gap to competitors "in recent history."ALEX: That's a fancy way of saying they're stealing customers from the competition! And speaking of the U.S., their value strategy seems to be working. They launched McValue early in the year, then relaunched Extra Value Meals in September. The results? They gained share with low-income consumers in December and saw meaningful improvement in value and affordability scores.JORDAN: The marketing machine was firing on all cylinders too. The MONOPOLY promotion became one of their largest digital customer acquisition events ever - they now have 46 million 90-day active users in their U.S. loyalty app alone. But get this - the Grinch Meal campaign set new sales records, including the highest single sales day in McDonald's history!ALEX: 50 million pairs of Grinch-themed socks sold globally! They literally became the largest seller of socks in the world for nearly a week. Only McDonald's could pull that off.JORDAN: The international segments held up well too. International Operated Markets grew comp sales 5.2% - that's three consecutive quarters above 4% growth. The U.K., Germany, and Australia all delivered mid-to-high single-digit comp growth, with each market gaining market share.ALEX: Now, let's talk about what's coming next because this is where it gets really interesting. They're accelerating restaurant openings - targeting 2,600 gross openings in 2026, up from 2,275 in 2025. That puts them on track for 50,000 restaurants by end of 2027.JORDAN: The capital expenditure guidance reflects this growth - they're expecting $3.7 to $3.9 billion in CapEx for 2026, up from $3.4 billion in 2025. CFO Ian Borden was clear this increase was planned and keeps them on track with their December 2023 investor day targets.ALEX: But here's what I found most intriguing - the menu innovation pipeline. New Chief Restaurant Experience Officer Jill McDonald outlined some ambitious plans. They're rolling out "Best Burger" to nearly all markets by end of 2026, and the Big Arch burger is gaining permanent spots on menus after successful pilots.JORDAN: And beverages - this could be huge, Alex. They're targeting a $100 billion global beverage opportunity with new offerings under the McCafe brand. Energy drinks, indulgent iced coffees, fruity refreshers, crafted sodas. They even mentioned continuing their Red Bull collaboration. Their beverage test in 500+ U.S. restaurants exceeded expectations and drove incremental occasions across different dayparts.ALEX: The chicken category focus is smart too - it's twice the size of beef and faster growing. They grew chicken category share across their top 10 markets in 2025 and are targeting at least 1 percenThis episode includes AI-generated content.

**Beta Finch - Episode 127: Coca-Cola Q4 2025**---**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we cut through the corporate speak to bring you what really matters. I'm Alex.**JORDAN:** And I'm Jordan. Today we're diving into Coca-Cola's Q4 2025 earnings call - and wow, what a historic moment this was.**ALEX:** Absolutely. Before we jump in though, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.**JORDAN:** So Alex, let's start with the elephant in the room - this was CEO James Quincey's final earnings call after a decade at the helm.**ALEX:** Right, and what a send-off! Quincey handed the reins to Henrique Braun, who's been with the company for over 30 years. But let's talk numbers first - Coca-Cola delivered on both their top and bottom line guidance for 2025, which is no small feat given the challenging macro environment.**JORDAN:** The headline numbers are solid. They achieved 4% comparable earnings per share growth despite facing 5 points of currency headwinds and a 2-point increase in their tax rate. That's actually pretty impressive when you break it down.**ALEX:** And they maintained their streak of gaining value share for 19 consecutive quarters. That's nearly five years of consistently winning market share, Jordan.**JORDAN:** Let's dig into the Q4 specifics because there's an interesting story in the price-mix numbers. They reported only 1% price-mix growth, but CFO John Murphy clarified that underlying pricing was actually 4%, with a 3% negative mix impact from geography and timing issues.**ALEX:** That's a perfect example of why Quincey urged analysts to take a "4-quarter view" rather than getting caught up in quarterly noise. When you smooth out the mix effects, you see consistent 5% revenue growth, which aligns with their long-term algorithm.**JORDAN:** Speaking of long-term, let's talk about their 2026 guidance. They're projecting 4% to 5% organic revenue growth and 7% to 8% comparable EPS growth. But here's the kicker - they're expecting a more balanced mix between volume and pricing going forward.**ALEX:** That's a key shift, Jordan. For the past few years, they've been heavily price-driven due to inflation. Now they're signaling a return to more balanced growth, which suggests they believe they can start winning back volume while maintaining pricing power.**JORDAN:** But it's not all smooth sailing. They're facing some headwinds in key markets. Mexico is implementing an excise tax that will pressure volumes, China continues to see softer consumer spending, and India needs to rebuild momentum after a challenging 2025.**ALEX:** New CEO Henrique Braun was pretty candid about this. He mentioned that their "all-weather strategy" helps them leverage strong markets to offset weaker ones. It's essentially a global portfolio approach - when one region struggles, others can pick up the slack.**JORDAN:** Let's talk about innovation because Braun made some interesting comments here. He said their innovation "is not where it needs to be" and they need to get closer to consumers and improve speed to market.**ALEX:** That was refreshingly honest. He talked about wanting to better anticipate the next growth opportunities in beverages and be more proactive rather than reactive. They announced two new billion-dollar brands - innocent and Santa Clara from Mexico - bringing their total to 32 billion-dollar brands.**JORDAN:** The Mexico example is fascinating because Santa Clara started as a local value-added dairy brand and grew into a billion-dollar business. That's exactly the playbook Braun wants to replicate - start local, learn what works, then scale globally.**ALEX:** Now let's talk about North America, which has been a real bright spoThis episode includes AI-generated content.

**Beta Finch Podcast Script: Johnson & Johnson Q4 2025**ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown where we dive deep into the numbers that matter. I'm Alex, and joining me as always is my co-host Jordan. Today we're dissecting Johnson & Johnson's Q4 2025 earnings call, and wow - what a way to cap off the year.Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.JORDAN: Thanks Alex, and yeah, JNJ really delivered here. They're calling 2025 a "catapult year" - and the numbers back that up. Let's start with the headline figures because they're impressive across the board.ALEX: Absolutely. Fourth quarter operational sales growth came in at 7.1%, which is solid, but the full-year picture is even better. They hit $94.2 billion in total revenue for 2025 with 5.3% operational growth. But here's the kicker, Jordan - they're guiding for $100 billion at the midpoint for 2026. That's a massive psychological milestone for any healthcare company.JORDAN: Right, and what's fascinating is how they're positioning this growth. CEO Joaquin Duato kept emphasizing their "28 billion-dollar products" - that's an incredible diversification of revenue streams. No other healthcare company has that kind of breadth. They're not relying on one or two blockbusters like some of their competitors.ALEX: Let's break down the two main segments. On the Innovative Medicine side, they posted 5.3% operational growth for the year, crossing $60 billion in pharma sales for the first time. The star performer here continues to be DARZALEX in multiple myeloma - $14 billion in annual sales with 22% growth. That's just staggering for a drug of that size.JORDAN: And they're not stopping there. The multiple myeloma franchise is becoming a juggernaut. They mentioned being the number one company in that space, with 80% of patients treated with at least one of their four medicines. Plus, CARVICTI, their CAR-T therapy, is showing strong momentum with over 10,000 patients treated across 14 markets.ALEX: The immunology story is equally compelling. Tremfya hit $5 billion in sales and grew 65% in Q4 - that's not a typo, sixty-five percent! They're confident it'll exceed $10 billion in peak sales, especially as it continues taking share in inflammatory bowel disease where STELARA used to dominate.JORDAN: Speaking of STELARA, that's the elephant in the room that's actually becoming less relevant. STELARA declined 48.6% due to biosimilar competition, but here's what's remarkable - JNJ grew double digits for the full year excluding STELARA. They've successfully navigated that cliff, which was a major investor concern.ALEX: Now let's talk MedTech. 5.4% operational growth for the year with some really strong pockets. Cardiovascular was the standout with 15% operational growth, reaching $9 billion. The Abiomed and Shockwave acquisitions are clearly paying dividends here.JORDAN: What caught my attention was their robotics ambition. They just submitted their Ottava robotic surgery system for FDA approval via a de novo pathway - meaning there's no predicate device to compare it against. That suggests they truly believe they have something differentiated in a space dominated by Intuitive Surgical.ALEX: The guidance for 2026 is aggressive but achievable based on their pipeline momentum. 5.7% to 6.7% operational sales growth, with that $100 billion midpoint I mentioned. Adjusted EPS growth of 5.5% at the midpoint, which factors in about $500 million in medtech tariffs - significantly higher than 2025.JORDAN: I want to highlight something CFO Joe Wolk said about margins. They're expecting at least 50 basis points of adjusted operating margin improvement despite those tariff headwinds and increased investment inThis episode includes AI-generated content.

**BETA FINCH PODCAST SCRIPT**---**ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex, and I'm here with my co-host Jordan to dive into Colgate-Palmolive's Q4 2025 results. Now, before we get into the toothpaste and pet food numbers, I need to share an important disclaimer: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.**JORDAN**: Thanks Alex. And speaking of brushing up on the details, Colgate just wrapped up what CEO Noel Wallace called a "stronger-than-expected Q4" despite some pretty challenging headwinds. The big story here isn't just the quarter though - it's their new 2030 strategy they're launching.**ALEX**: Right, so let's start with the numbers. What stood out to you from the quarter?**JORDAN**: Well, the momentum story is compelling. They saw sequential improvement in organic sales growth across most regions - hitting over 3% organic growth when you exclude their planned exit from private label business. That's a nice acceleration from Q3. And importantly, they delivered modest volume growth in Q4, which is no small feat in this environment.**ALEX**: And the cash flow performance was pretty impressive too, right?**JORDAN**: Absolutely stellar - record operating cash flow of $4.2 billion. That's giving them serious flexibility for reinvestment and potential acquisitions. Wallace kept emphasizing this "flexibility" theme throughout the call.**ALEX**: Now, the guidance for 2026 was interesting - they gave a pretty wide range of 1% to 4% for organic sales growth. That's unusually broad for Colgate.**JORDAN**: Yeah, and Wallace was refreshingly transparent about why. He basically said: if categories get worse, they'll be at the low end. If categories stay where they are, they'll be in the middle. If categories strengthen, they hope to hit the higher end. It's a simple framework, but it shows just how uncertain they feel about the consumer environment right now.**ALEX**: Speaking of uncertainty, the U.S. market seems to be their biggest challenge. What's happening there?**JORDAN**: It's pretty stark. Wallace mentioned that nine of their categories were down in volume in October, ten in November. The North American business is clearly struggling with what he called "consumer uncertainty." People are holding back on filling their pantries, buying more on promotion, and there's this general sluggishness in category growth.**ALEX**: But there were some bright spots internationally, weren't there?**JORDAN**: Definitely. Latin America had a really strong quarter - both Mexico and Brazil growing high single digits. And their emerging markets overall grew about 4.5% organically with good balance between price and volume. It's that classic story of developed markets struggling while emerging markets show more resilience.**ALEX**: The Hill's pet food business also seemed to perform well despite a tough category backdrop.**JORDAN**: Hill's was a standout - over 5% growth excluding private label, with positive volume growth. Their prescription diet business is really driving growth, and that higher-margin therapeutic segment is exactly where you want to see momentum. Wallace mentioned they're gaining share across all channels.**ALEX**: Now, let's talk about this 2030 strategy they unveiled. It sounds like a pretty significant shift.**JORDAN**: It's fascinating - they're basically reorganizing around what they call "omnichannel demand generation." Instead of having separate e-commerce and brick-and-mortar teams, they're creating one integrated commercial organization. Wallace said they've been sending leaders to China to learn from their team there, which has figured out how to excel in both traditional retail and online.**ALEX**: And they're backing this up with their StThis episode includes AI-generated content.

**Beta Finch Podcast Script: Abbott Laboratories Q4 2025 Earnings**---**ALEX:** Welcome back to Beta Finch, your AI-powered earnings breakdown where we dive deep into the numbers that move markets. I'm Alex, and as always, I'm joined by my co-host Jordan. Today we're unpacking Abbott's fourth quarter 2025 results, and folks, there's quite a story here.Before we jump in, I need to share our standard disclaimer: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.Now Jordan, Abbott just reported their Q4 numbers, and CEO Robert Ford had some interesting things to say about the year ahead. What caught your attention first?**JORDAN:** Alex, the headline numbers tell a tale of two companies, honestly. On one hand, you've got Abbott delivering on their original double-digit EPS growth target with adjusted earnings per share hitting $1.50 – that's 12% growth year-over-year. But then there's this nutrition business headwind that's creating some near-term challenges.**ALEX:** Right, and let's talk about that guidance because it's pretty telling. For 2026, Abbott is projecting organic sales growth of 6.5% to 7.5% – so 7% at the midpoint – and they're calling for 10% growth in adjusted EPS. That EPS growth is solid, but that revenue guidance seems a bit more cautious than what some were expecting.**JORDAN:** Exactly, and Ford was pretty transparent about why. The nutrition business is essentially going through what he called a "transition back to a more sustainable volume-driven business." Here's what's fascinating – Abbott has been raising prices to offset post-pandemic commodity cost increases, but now those higher prices are actually suppressing demand as consumers become more price-sensitive.**ALEX:** It's like a classic consumer goods dilemma, right? You raise prices to maintain margins, but eventually you price yourself out of volume growth. Ford mentioned they started implementing "price and promotion initiatives" in Q4 to try to reignite volume growth. How big of an impact is this having on the overall company?**JORDAN:** Well, nutrition is a meaningful piece of Abbott's portfolio, but what I found encouraging is how Ford framed the rest of the business. He said a "significant majority of the company" is either maintaining high single-digit growth or actually accelerating. The medical devices segment, for example, grew 10.5% in the quarter.**ALEX:** And that medical devices growth is really impressive when you dig into the details. Continuous glucose monitors grew 17% for the full year, exceeding $7.5 billion in sales. That's the third consecutive year their CGM business has grown by more than a billion dollars. Jordan, when an analyst asked about CGM growth expectations, Ford had a pretty confident response.**JORDAN:** He did! Ford pushed back on the narrative that the CGM market is slowing down, saying "I don't consider growing a billion dollars every single year and doing it four years in a row to be slowing down." He sees continued penetration opportunities across all patient groups – intensive insulin users, basal insulin users, and non-insulin users. Plus, there's potential for expanded reimbursement coverage for non-insulin Type 2 diabetes patients.**ALEX:** Speaking of new products, Abbott got FDA approval for their BOLT PFA catheter in December and CE Mark approval for their Tactiflex Duo ablation catheter. Ford seemed pretty excited about their electrophysiology portfolio positioning.**JORDAN:** Absolutely. He made this great point about how three years ago, there were concerns that Abbott's EP franchise would struggle without PFA technology, but they've maintained double-digit growth even without those products. Now with Volt launching in the US and Tactiflex Duo internationally, Ford said "I doThis episode includes AI-generated content.